ESSA Pharma Will Fit Into Xtandi, Zytiga Prostate Cancer Treatment Gaps

Emerging Company Profile: ESSA Pharma, a publically traded cancer R&D company, believes it has the answer to drug resistance in patients treated with best-selling cancer therapies Xtandi and Zytiga – as it targets last-line patients with a prostate cancer therapy based on a new mechanism of action.